TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.

Humans Mutation Neoplasms / drug therapy Oncogenes Protein Kinase Inhibitors / pharmacology Receptor, trkA / genetics

Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
01 2021
Historique:
received: 01 05 2020
revised: 26 08 2020
accepted: 28 09 2020
pubmed: 3 10 2020
medline: 5 6 2021
entrez: 2 10 2020
Statut: ppublish

Résumé

On-target resistance to next-generation TRK inhibitors in TRK fusion-positive cancers is largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations confer resistance to type I next-generation TRK inhibitors designed to maintain potency against several kinase domain mutations. Computational modeling and biochemical assays showed that TRKA

Identifiants

DOI: 10.1158/2159-8290.CD-20-0571 PMID: 33004339 PMC: PMC8012405
pubmed: 33004339
pii: 2159-8290.CD-20-0571
doi: 10.1158/2159-8290.CD-20-0571
pmc: PMC8012405
mid: NIHMS1634943
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Receptor, trkA EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-141

Subventions

Organisme : NCI NIH HHS
ID : T32 CA160001
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181746
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009207
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204749
Pays : United States
Organisme : NIH HHS
ID : S10 OD023669
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226864
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

J Thorac Oncol. 2017 Nov;12(11):1611-1625
pubmed: 28818606
Scand J Gastroenterol Suppl. 1995;208:1-148
pubmed: 7777788
Nat Rev Clin Oncol. 2018 Nov;15(11):694-708
pubmed: 30108370
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Leukemia. 2015 Dec;29(12):2390-2
pubmed: 26108694
Clin Cancer Res. 2019 Jun 1;25(11):3341-3351
pubmed: 30796031
Cancer Discov. 2017 Sep;7(9):963-972
pubmed: 28578312
J Med Chem. 2018 Aug 9;61(15):6779-6800
pubmed: 29944371
PLoS Comput Biol. 2015 Nov 25;11(11):e1004578
pubmed: 26606374
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Nat Rev Clin Oncol. 2017 Dec;14(12):735-748
pubmed: 28857077
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
J Med Chem. 2015 Jan 8;58(1):466-79
pubmed: 25478866
Nat Rev Drug Discov. 2018 May;17(5):353-377
pubmed: 29545548
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Clin Genitourin Cancer. 2018 Oct;16(5):e1069-e1071
pubmed: 30005936
Nat Med. 2019 Sep;25(9):1422-1427
pubmed: 31406350
Nat Commun. 2018 Feb 12;9(1):625
pubmed: 29434222
Cancer Discov. 2016 Dec;6(12):1334-1341
pubmed: 27694386
Nat Commun. 2017 Jul 11;8:15987
pubmed: 28695888
Expert Opin Investig Drugs. 2020 Jan;29(1):73-85
pubmed: 31783719
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Oncotarget. 2018 Feb 13;9(17):13796-13806
pubmed: 29568395
Clin Cancer Res. 2016 May 15;22(10):2351-8
pubmed: 26673800
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
Cell Chem Biol. 2019 Sep 19;26(9):1240-1252.e11
pubmed: 31257184
Cancer Discov. 2016 Jan;6(1):36-44
pubmed: 26546295
Chem Biol. 2013 Jun 20;20(6):806-15
pubmed: 23790491
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6818-6827
pubmed: 30867294
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55
pubmed: 32760015
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
Ann Oncol. 2016 May;27(5):920-6
pubmed: 26884591
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10025-10030
pubmed: 31043566
Mol Cancer Ther. 2017 Oct;16(10):2130-2143
pubmed: 28751539
PLoS Comput Biol. 2012;8(8):e1002661
pubmed: 22927810
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Future Oncol. 2019 Aug;15(22):2585-2593
pubmed: 31339066

Auteurs

Emiliano Cocco (E)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Ji Eun Lee (JE)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0001-9187-8641

Srinivasaraghavan Kannan (S)

Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore.
ORCID: 0000-0002-9539-5249

Alison M Schram (AM)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.
ORCID: 0000-0002-6070-2413

Helen H Won (HH)

Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0001-5237-7529

Sophie Shifman (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Amanda Kulick (A)

Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Laura Baldino (L)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Eneda Toska (E)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Amaia Arruabarrena-Aristorena (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-1636-3944

Srushti Kittane (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Fan Wu (F)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-3960-320X

Yanyan Cai (Y)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Sabrina Arena (S)

Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
ORCID: 0000-0002-1318-2494

Benedetta Mussolin (B)

Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
ORCID: 0000-0001-5723-5685

Ram Kannan (R)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-9539-5249

Neil Vasan (N)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Alexander N Gorelick (AN)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0001-6736-8246

Michael F Berger (MF)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Ofra Novoplansky (O)

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID: 0000-0002-1239-7856

Sankar Jagadeeshan (S)

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID: 0000-0002-3778-8757

Yi Liao (Y)

Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida.

Uwe Rix (U)

Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida.
ORCID: 0000-0002-8242-2770

Sandra Misale (S)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Barry S Taylor (BS)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Alberto Bardelli (A)

Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.

Jaclyn F Hechtman (JF)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

David M Hyman (DM)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Moshe Elkabets (M)

The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID: 0000-0003-3634-9098

Elisa de Stanchina (E)

Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Chandra S Verma (CS)

Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.
School of Biological Sciences, Nanyang Technological University, Singapore.
Department of Biological Sciences, National University of Singapore, Singapore.

Andrea Ventura (A)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.

Alexander Drilon (A)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.
Weill Cornell Medical College, New York, New York.
ORCID: 0000-0001-6806-9061

Maurizio Scaltriti (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-5522-1447

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › TRK xDFG Mutations Trigger a Sensitivity...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › TRK xDFG Mutations Trigger a Sensitivity...
questionsmedicales.fr › Tumeurs › TRK xDFG Mutations Trigger a Sensitivity...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes tumoraux › Oncogènes › TRK xDFG Mutations Trigger a Sensitivity...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › TRK xDFG Mutations Trigger a Sensitivity...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs facteur croissance nerf › Récepteur trkA › TRK xDFG Mutations Trigger a Sensitivity...